Patients' preferences for headache acute and preventive treatment | All the latest summaries on the portal Medznat.ru. :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Patients' preferences for headache acute and preventive treatment

Patients' preferences for headache acute and preventive treatment Patients' preferences for headache acute and preventive treatment
Patients' preferences for headache acute and preventive treatment Patients' preferences for headache acute and preventive treatment

To examine patients' choices for headache therapies with a self-administered questionnaire involving the Q-No questionnaire for nocebo.

See All

Key take away

Several newer therapeutic formulations with more modern mechanisms are invited for the treatment of migraine and headache developed an explosive environment in the field of medicine. The patients’ perspectives and preferences should be taken into account while prescribing the medication. In this research, the author determines the patient preferences along with efficacy and safety data may help physicians to choose the right treatment for the right person. 

Background

To examine patients' choices for headache therapies with a self-administered questionnaire involving the Q-No questionnaire for nocebo.

Method

A total of 514 patients who naïve to neurostimulation and monoclonal antibodies have completed the questionnaires.

Result

Patients focused on the treatment's efficacy rather than the route of administration or safety of the administrated drug. For both acute and preventive treatment, patients preferred an external neurostimulation device. For symptomatic pharmaceutical treatment, several patients opt for a pill than any other medication administered parenterally. For preventive pharmaceutical treatment, many of the patients go for a pill once per day (52%) than an injection either intravenously or subcutaneously every month, or three months. In Q-No questionnaire, 56.6% of out of all participants scored more than 15, showing potential nocebo behaviours that contributed considerably to their decisions.

Conclusion

The patient choices along with safety and efficacy information may assist physicians expertly choose the right therapy for the right person.

Source:

J Headache Pain. 2017 Oct 6;18(1):102

Article:

Patients' preferences for headache acute and preventive treatment

Authors:

Mitsikostas DD et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: